Read More 30 minute read Intraday Update Markets Movers News Options Trading Ideas Stocks That Hit 52-Week Lows On Tuesday By Benzinga Insights February 22, 2:19 PM During Tuesday's trading, 505 companies set new 52-week lows. ACRX
Read More 19 minute read Intraday Update Markets Movers News Options Trading Ideas Stocks That Hit 52-Week Lows On Friday By Benzinga Insights February 18, 11:53 AM On Friday, 313 companies hit new 52-week lows. AAON
Read More 5 minute read Intraday Update Markets News Options Stocks That Hit 52-Week Lows On Monday By Benzinga Insights February 7, 12:59 PM On Monday, 71 stocks hit new 52-week lows. ACLX
Read More 2 minute read Intraday Update Markets Movers 12 Health Care Stocks Moving In Tuesday’s Intraday Session By Benzinga Insights January 18, 1:42 PM ARCT
Read More 6 minute read Intraday Update Markets Movers News Options Trading Ideas Stocks That Hit 52-Week Lows On Tuesday By Benzinga Insights January 11, 11:38 AM During Tuesday's morning trading, 87 companies set new 52-week lows. AAOI
Read More 7 minute read Intraday Update Markets Movers News Options Trading Ideas Stocks That Hit 52-Week Lows On Friday By Benzinga Insights January 7, 11:39 AM Before 10 am on Friday, 110 companies set new 52-week lows. ACHR
Read More 3 minute read Biotech FDA General Guidance News Ayala Pharma Offers Key Business Objectives For 2022 By Benzinga Newsdesk January 4, 9:27 AM -- Data read-outs expected on AL102 in desmoid tumors and AL101 in ACC and TNBC -- REHOVOT, Israel and WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a AYLA
Read More 11 minute read Analyst Ratings Downgrades Initiation Intraday Update Upgrades Benzinga’s Top Ratings Upgrades, Downgrades For December 20, 2021 By Benzinga Insights December 20, 12:58 PM ANTM
Read More 1 minute read Analyst Ratings Initiation News Price Target Maxim Group Initiates Coverage On Ayala Pharmaceuticals with Buy Rating, Announces Price Target of $22 By Benzinga Newsdesk December 20, 10:31 AM Maxim Group analyst Naureen Quibria initiates coverage on Ayala Pharmaceuticals (NASDAQ:AYLA) with a Buy rating and announces Price Target of $22. AYLA
Read More 1 minute read Analyst Ratings News Price Target Upgrades Jefferies Upgrades Ayala Pharmaceuticals to Buy, Raises Price Target to $17 By Benzinga Newsdesk November 30, 7:55 AM Jefferies analyst Maury Raycroft upgrades Ayala Pharmaceuticals (NASDAQ:AYLA) from Hold to Buy and raises the price target from $12 to $17. AYLA